{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-017844","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.560969+00:00","generated_at":"2026-05-23T15:15:20.144624+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO","bullets":["Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.","Daniel Apel, former Global Head of FP&A at Walgreens Boots Alliance and Bayer US CFO, appointed CFO same date.","Apel receives $575K base salary, 45% target bonus, 100K RSUs vesting over 4 years, and up to $200K relocation.","Myszkowski will serve as adviser through Jan 31, 2026, at $200K annual salary with continued benefits and equity vesting.","CEO cites transition to commercial stage with planned plozasiran launch pending regulatory review."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-017844","json":"https://secwatch.observer/filing/0001628280-25-017844.json","markdown":"https://secwatch.observer/filing/0001628280-25-017844.md","text":"https://secwatch.observer/filing/0001628280-25-017844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/0001628280-25-017844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/arwr-20250411.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:15:20.144624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60021b221a","claim":"Ken Myszkowski departed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..","evidence_excerpt":"Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/0001628280-25-017844-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6740d8fcff","claim":"Daniel Apel was appointed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..","evidence_excerpt":"the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/0001628280-25-017844-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}